[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Brainfarma Industria Química e Farmacêutica S\u002FA\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":155},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,65,85,122],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100652487","dermal-and-ophthalmological-acceptability-assessment-in-sensitive-skin-100652487",false,"NCT07771998","Dermal and Ophthalmological Acceptability Assessment in Sensitive Skin","Evaluation of the Dermal and Ophthalmological Acceptability of Blancy Pro in Subjects With Sensitive Skin","ADOPS","Inclusion Criteria:\n\n* Female participants aged 18 to 60 years.\n* Participants with any skin type, with at least 25% representation of each skin type.\n* Participants with sensitive skin, clinically confirmed by the Stinging Test.\n* Intact skin in the assessment area.\n* Willingness to comply with all study procedures and attend scheduled visits and assessments.\n* Ability to understand, provide written informed consent, and sign the Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women, or women at risk of becoming pregnant during the study.\n* Use of anti-inflammatory, immunosuppressive, or antihistamine medications within 3 weeks prior to screening.\n* Skin marks or conditions in the study area that may interfere with the evaluation of skin reactions, including vascular malformations, scars, excessive hair growth, multiple nevi, or sunburn.\n* History of atopic disease or allergy to cosmetic products.\n* Active skin diseases and\u002For lesions in the assessment area or elsewhere on the body.\n* Immunosuppression due to medication use or active disease.\n* Uncontrolled endocrine disorders.\n* Relevant medical history or current evidence of alcohol or drug abuse.\n* Known history or suspected intolerance to products of the same category as the investigational product.\n* Intense sun exposure within 15 days prior to assessment.\n* Aesthetic or dermatological treatments within 4 weeks prior to assessment.\n* Any other condition that, in the investigator's opinion, may justify exclusion from the study. Reasons for exclusion will be documented in the clinical record.\n* Participants with entropion, ectropion, hordeolum (stye), conjunctivitis, uveitis, or other active ocular diseases at screening.\n* Participants with corneal ulceration, blepharitis, meibomitis, pterygium, trichiasis, distichiasis, or other moderate to severe ocular disorders.\n* Initiation of contact lens use within 1 week prior to screening.\n* Use of ophthalmic products, including eye drops and\u002For ophthalmic ointments, within 3 weeks prior to screening.\n* Any other ocular condition that, in the investigator's opinion, may justify exclusion from the study. Reasons for exclusion will be documented in the clinical record.",true,"FEMALE","18 Years","60 Years",{"count":22,"type":23},33,"ESTIMATED","INTERVENTIONAL",[26],"NA","This is a single-center, single-blind clinical study designed to evaluate the safety of the investigational product through dermatological and ophthalmological clinical assessments. A total of 33 female participants, aged 18 to 60 years, with a clinical diagnosis of sensitive skin confirmed by the Stinging Test, will be enrolled. Safety evaluations will be performed throughout the study period using standardized clinical assessments.",[29],"Sensitive Skin","RECRUITING","2026-08-17",{"date":33,"type":34},"2026-08-19","ACTUAL",{"date":36,"type":34},"2026-07-20",{"date":38,"type":23},"2026-09-03",{"name":40,"class":41},"Brainfarma Industria Química e Farmacêutica S\u002FA","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":17,"sex":18,"minAge":51,"maxAge":20,"enrollmentInfo":52,"targetDuration":4,"studyType":24,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":59,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":42},"100651951","efficacy-evaluation-of-a-cosmetic-product-for-facial-hyperpigmentation-100651951","NCT07769268","Efficacy Evaluation of a Cosmetic Product for Facial Hyperpigmentation","Evaluation of the Efficacy of a Cosmetic Product for the Reduction of Facial Hyperpigmentation: A Clinical, Subjective, and Instrumental Study","HYPERPIG","Inclusion Criteria:\n\n* Female participants aged 30 to 60 years.\n* Group I: Participants with Fitzpatrick skin phototypes I to VI, with at least one participant from each phototype category. Participants with facial hyperpigmentation, including post-inflammatory hyperpigmentation and solar lentigines.\n* Group II: Participants with moderate or greater melasma, as assessed by the modified Melasma Area and Severity Index (mMASI), and Fitzpatrick skin phototypes II to V.\n* Willingness to comply with all study procedures and attend scheduled on-site visits and assessments.\n* Willingness to comply with study procedures and be available for remote contact (telehealth) at scheduled times.\n* Ability to understand the study requirements, provide written informed consent, and sign the informed consent form.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women, or women at risk of becoming pregnant during the study.\n* Use of anti-inflammatory, immunosuppressive, or antihistamine medications within 3 weeks prior to screening.\n* Skin conditions or marks in the study area that may interfere with the evaluation of skin reactions, including vascular malformations, scars, excessive hair growth, multiple nevi, or sunburn.\n* History of atopic conditions or allergy to cosmetic products.\n* Active skin diseases and\u002For lesions in the assessment area.\n* Immunosuppression due to medication use or active disease.\n* Uncontrolled endocrine disorders.\n* Relevant medical history or current evidence of alcohol or substance abuse.\n* Known history or suspected intolerance to products of the same category as the study product.\n* Intense sun exposure within 15 days prior to assessment.\n* Aesthetic or dermatological treatments within 4 weeks prior to assessment.\n* Any other condition that, in the investigator's opinion, may interfere with study participation or justify exclusion from the study.","30 Years",{"count":53,"type":23},40,[26],"This is a single-center, single-blind clinical study designed to evaluate the efficacy of a depigmenting gel cream through clinical, subjective, and instrumental assessments. A total of 40 female participants, aged 30 to 60 years, will be enrolled and followed for 90 days while using the study product.Participants will be assigned to one of two groups. Group I will include 20 participants with facial hyperpigmentation, including post-inflammatory hyperpigmentation and solar lentigines, representing Fitzpatrick skin phototypes I to VI, with at least one participant from each phototype. Group II will include 20 participants with moderate or greater melasma, as assessed by the modified Melasma Area and Severity Index (mMASI), representing Fitzpatrick skin phototypes II to V.\n\nThe study aims to evaluate the product's effectiveness in reducing facial hyperpigmentation and improving skin appearance over the treatment period.",[57,58],"Hyperpigmentation","Melasma (Facial Melasma)",{"date":33,"type":34},{"date":61,"type":34},"2026-07-13",{"date":63,"type":23},"2027-01-21",{"name":40,"class":41},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":24,"phases":75,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":81,"completionDateStruct":82,"leadSponsor":84,"locationsCount":42},"100651927","evaluation-of-dermal-acceptability-and-comedogenic-and-acnegenic-potential-of-a-cosmetic-product-100651927","NCT07768800","Evaluation of Dermal Acceptability and Comedogenic and Acnegenic Potential of a Cosmetic Product","Clinical Evaluation of Dermal Acceptability and the Comedogenic and Acnegenic Potential of a Cosmetic Product","DACP","Inclusion Criteria:\n\n* Female participants aged 18 to 45 years.\n* Participants with oily and acne-prone skin.\n* Intact skin in the area intended for application and assessment of the investigational product.\n* Willingness to comply with all study procedures and attend scheduled visits and assessments.\n* Ability to understand the study requirements, provide written informed consent, and sign the Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women, or women at risk of becoming pregnant during the study.\n* Use of anti-inflammatory, immunosuppressive, or antihistamine medications within 3 weeks prior to screening.\n* Skin conditions or marks in the study area that may interfere with the evaluation of skin reactions, including vascular malformations, scars, excessive hair growth, multiple nevi, or sunburn.\n* History of atopic conditions or allergy to cosmetic products.\n* Active skin diseases and\u002For lesions in the assessment area or elsewhere on the body.\n* Immunosuppression due to medication use or active disease.\n* Uncontrolled endocrine disorders.\n* Relevant medical history or current evidence of alcohol or substance abuse.\n* Known history or suspected intolerance to products of the same category as the investigational product.\n* Intense sun exposure within 15 days prior to assessment.\n* Aesthetic or dermatological treatments within 4 weeks prior to assessment.\n* Any other condition that, in the investigator's opinion, may interfere with study participation, study evaluations, or justify exclusion from the study.","45 Years",{"count":22,"type":23},[26],"This is a single-center, single-blind clinical study designed to evaluate the dermatological safety of a cosmetic product and to demonstrate the absence of comedogenic and acnegenic potential.\n\nA total of 33 female participants, aged 18 to 60 years, with oily and acne-prone skin will be enrolled. Participants will use the investigational product for 28 days under normal conditions of use.\n\nDermatological safety, skin tolerability, and the absence of comedogenic and acnegenic effects will be assessed throughout the study period by clinical evaluations conducted according to the study protocol.",[78],"Oily Skin","2026-08-12",{"date":31,"type":34},{"date":36,"type":34},{"date":83,"type":23},"2026-09-17",{"name":40,"class":41},{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":93,"minAge":19,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":24,"phases":97,"briefSummary":89,"conditions":99,"keywords":103,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":115,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},"100647919","phase-3-extended-release-pregabalin-for-the-treatment-of-neuropathic-pain-in-patients-with-diabetic-peripheral-neuropathy-and-postherpetic-neuralgia-100647919","NCT07712913","Extended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia","A Phase III, Multicenter, Randomized, Double-blind, Double-dummy, Controlled, Parallel-group, Non-inferiority Clinical Trial to Evaluate the Efficacy and Safety of Extended-release Pregabalin Tablets Compared With Immediate-release Pregabalin Tablets, in the Relief of Neuropathic Pain in Participants With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia.","PRISE","Inclusion Criteria:\n\nThe following criteria must be met for a participant to be included in the study:\n\n1. Participants of either sex, aged 18 to 75 years.\n2. Be able to understand and agree to participate in the study, undergo the procedures, and attend the visits, as indicated by signing the informed consent form approved by the CEP\u002FConep System.\n3. Have a diagnosis of peripheral neuropathic pain associated with:\n\n   * diabetes mellitus (type 1 or 2), with glycated hemoglobin (HbA1c) levels ≤ 11%, documented symptoms of peripheral diabetic neuropathy for at least 6 months, and use of medication for glycemic control at a stable dose for at least 30 days.\n   * postherpetic neuralgia, with pain symptoms for at least 3 months following a skin rash due to an acute episode of herpes zoster.\n4. Presence of neuropathic pain, with an intensity of ≥ 4 on the 11-point DPRS numerical scale (from 0 \"no pain\" to 10 \"worst possible pain\"‡). ‡ Pain intensity ≥ 4 will be confirmed at the initial visit (IV); during the screening\u002Frandomization visit, Participant Diary No. 1 containing the DPRS scales will be provided, in which the participant will record pain intensity daily upon waking and at the end of the day for 7 days (±2 days). The mean value for pain intensity recorded during the Screening\u002FRandomization Phase will be used to confirm eligibility at the initial visit (IV).\n5. Participants who are unable to become pregnant (postmenopausal women, defined as 12 months or more of amenorrhea, or who have undergone surgical sterilization\\*; and men who have undergone vasectomy\\*\\*) OR participants of reproductive potential who agree to use a reliable method of contraception\\*\\*\\*.\n\n   * Female sterilization (undergoing bilateral surgical oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least 6 weeks prior to administration of the investigational drug.\n\n     * Male sterilization at least 6 months prior to screening. \\*\\*\\* If the participant is of childbearing age and decides to participate in the study, they must use or request that their partner use a safe contraceptive method. A safe contraceptive method is defined as the use of at least one of the following: condoms, a diaphragm, and\u002For a hormonal method (estrogenic and\u002For progestogenic) in the form of medication, including oral, vaginal, injectable, transdermal, and intrauterine devices. Only participants who expressly declare themselves exempt from the risk of pregnancy-whether because they do not engage in sexual activity or because they engage in it in a non-reproductive manner-will have the right to participate in the study without the mandatory use of contraceptives. Examples include participants who have undergone a vasectomy, those with an infertile partner, or those practicing total heterosexual abstinence.\n\nThe decision regarding the best contraceptive method to use will be made jointly by the physician and the study participant. If there are any costs involved, the chosen contraceptive method will be provided by the sponsor free of charge for as long as necessary. In addition, condoms with spermicide will be provided to participants at all study visits, when applicable.\n\nExclusion Criteria:\n\nA positive response to any of the following criteria will exclude the participant from the study:\n\n1. The presence of pain unrelated to the primary diagnosis of diabetic peripheral neuropathy or postherpetic neuralgia that could interfere with the evaluation.\n2. Any skin condition that potentially alters sensation in the affected dermatome or area of neuropathic involvement, which could interfere with the assessment.\n3. Having undergone neurosurgical therapy for the treatment of neuropathy.\n4. Current use, or use within the past 7 days, of nerve block therapy and\u002For medications commonly used to treat neuropathic pain (e.g., benzodiazepines, skeletal muscle relaxants, capsaicin, local anesthetics, opioids, memantine), antiepileptic drugs (e.g., carbamazepine, clonazepam, phenytoin, valproic acid, lamotrigine, topiramate, gabapentin), antidepressants (e.g., tricyclics, serotonin reuptake inhibitors, venlafaxine), and potential neurotoxins (e.g., hydroxychloroquine, deferoxamine, thioridazine, vigabatrin).\n5. History of treatment failure or hypersensitivity to pregabalin or gabapentin.\n6. History of neoplastic disease within the past 2 years (excluding basal cell carcinoma), neurological disease, unstable heart disease, psychiatric conditions (particularly suicidal ideation), and\u002For infection with hepatitis B, hepatitis C, or HIV.\n7. Current laboratory abnormalities in liver enzymes (elevated AST and\u002For ALT 2.5 times the upper limit of the reference range) and\u002For renal insufficiency (glomerular filtration rate \\\u003C 60 mL\u002Fmin\u002F1.73 m²).\n8. History of illicit drug abuse in the past 2 years.\n9. History of alcoholism (average alcohol intake exceeding 3 standard drinks\\* per day or more than 7 standard drinks per week for women, and exceeding 4 standard drinks per day or more than 14 standard drinks per week for men) in the past 2 years.\n\n   \\* A standard drink is: a can of regular beer (330 mL at 4%); a shot of distilled spirits (30 mL at 40%); a glass of wine or a small glass of sherry (100 mL at 12% or 70 mL at 18%); a small glass of liqueur or similar (50 mL at 25%) (53).\n10. Being pregnant, breastfeeding, or intending to become pregnant during the study period.\n11. Having participated in clinical studies in the past 12 (twelve) months, unless there may be a direct benefit to the study participant, at the investigator's discretion.\n12. Having any condition that prevents participation, at the investigator's discretion.","ALL","75 Years",{"count":96,"type":23},348,[98],"PHASE3",[100,101,102],"Diabetic Neuropathy","Neuropathic Pain","Neuralgia, Postherpetic",[104,105,106,107,108,109,110,111,112,113,114],"multicenter","randomized","double-blind","double-dummy","controlled","parallel-group","non-inferiority","diabetic","postherpetic neuralgia","peripheral neuropathy","Pregabalin",{"date":36,"type":34},{"date":117,"type":34},"2026-06-18",{"date":119,"type":23},"2027-06-01",{"name":40,"class":41},15,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":93,"minAge":19,"maxAge":20,"enrollmentInfo":130,"targetDuration":4,"studyType":24,"phases":132,"briefSummary":133,"conditions":134,"keywords":138,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":121},"100642484","phase-3-fixed-dose-combination-of-1000-mg-dipyrone-monohydrate--60-mg-caffeine--4-mg-chlorpheniramine-maleate-in-improving-symptoms-of-the-common-cold-and-flu-in-adults-100642484","NCT07626437","Fixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate in Improving Symptoms of the Common Cold and Flu in Adults","A Phase III, Multicenter, Double-blind, Randomized, Parallel-group Non-inferiority Clinical Trial to Evaluate the Efficacy and Safety of a Fixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate Compared to Benegrip® in Improving Symptoms of the Common Cold and Flu in Adult Participants","PANAMA","Inclusion Criteria:\n\n* The following criteria must be met for the participant to be included in the study:\n\n  1. Participants of both sexes, aged between 18 and 60 years.\n  2. Be able to understand, agree to participate in the study, comply with procedures, and attend visits, as indicated by signing the informed consent form (ICF) approved by the Ethics Committee.\n  3. Present symptoms of nasal obstruction and\u002For congestion due to the common cold or influenza, with onset within less than 48 hours, with symptoms classified by the participant as moderate to severe on a 4-point scale (0 = no symptoms; 1 = mild symptoms; 2 = moderate symptoms; 3 = severe symptoms).\n  4. Must not have used any medication for symptomatic treatment of the condition.\n  5. Female participants without childbearing potential, defined as postmenopausal women (defined as 12 months or more of amenorrhea) or those who have undergone surgical sterilization\\*, OR female participants with reproductive potential who agree to use a reliable contraceptive method\\*\\*.\n\n     \\* Female sterilization (bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation performed at least 6 weeks before administration of the investigational product.\n\n     \\*\\* If the participant is of childbearing potential and decides to participate in the study, she must use or request that her partner use a reliable contraceptive method. Reliable contraception is defined as the use of at least one of the following: condoms, diaphragm, and\u002For hormonal contraceptive methods (estrogenic and\u002For progestogenic), including oral, vaginal, injectable, transdermal, implantable, and intrauterine devices. Only participants who explicitly declare no risk of pregnancy, either due to not engaging in sexual activity or engaging exclusively in non-reproductive practices, may participate without mandatory contraceptive use; for example: participants with a sterile or vasectomized partner (at least 6 months before screening), or total heterosexual abstinence.\n\n     Exclusion Criteria:\n* A positive response to any of the following criteria will exclude the participant from the study:\n\n  1. Participants with COVID-19, diagnosed by rapid antigen test and\u002For RT-PCR for SARS-CoV-2;\n  2. Previous contact with individuals diagnosed with COVID-19 within 14 days prior to screening;\n  3. Vaccination against influenza and\u002For COVID-19 within 7 days prior to the study;\n  4. Presence of gastrointestinal symptoms and\u002For dyspnea associated with cold or flu symptoms;\n  5. Clinical history consistent with bacterial upper respiratory tract infection requiring antibiotic therapy;\n  6. History of grade II or III septal deviation, nasal polyps, marked turbinate hypertrophy, adenoid hypertrophy, chronic sinusitis (or recent episode within the last 2 weeks), rhinitis (seasonal allergic, drug-induced, vasomotor, atrophic, or other), or other conditions causing nasal obstruction;\n  7. Diagnosis of: congenital glucose-6-phosphate dehydrogenase deficiency, prothrombin deficiency, gastroduodenal ulcer, hepatic porphyria, narrow-angle glaucoma, chronic nephritis, blood dyscrasias, asthma, chronic respiratory infection, chronic respiratory disease, severe cardiocirculatory conditions, or immunocompromised status;\n  8. History of hypersensitivity to analgesics, antirheumatic drugs, and\u002For alcoholic beverages;\n  9. Participants allergic to foods, hair dyes, and\u002For preservatives;\n  10. Participants dependent on decongestants (topical, nasal, or oral) or receiving allergen-specific immunotherapy;\n  11. Use of monoamine oxidase inhibitors (phenelzine, iproniazid, isocarboxazid, harmaline, nialamide, pargyline, selegiline, toloxatone, tranylcypromine, moclobemide), cyclosporine, chlorpromazine, barbiturates (phenobarbital, thiopental, methohexital, pentobarbital), hypnotics (triazolam, midazolam, oxazepam, chlordiazepoxide, clonazepam), narcotic analgesics (morphine, codeine, meperidine), sedatives, and\u002For tranquilizers;\n  12. History of alcoholism (average alcohol intake exceeding 3 standard drinks\\* in a single day or more than 7 drinks per week for women, and more than 4 drinks in a single day or more than 14 drinks per week for men);\n\n      * One standard drink is defined as: one can of regular beer (330 mL at 4%); one serving of distilled spirits (30 mL at 40%); one glass of wine or small glass of sherry (100 mL at 12% or 70 mL at 18%); one small glass of liqueur or similar (50 mL at 25%).\n  13. Pregnant or breastfeeding women, or those intending to become pregnant during the study period;\n  14. Participation in a clinical study within the last 12 months, at the investigator's discretion;\n  15. Any condition that, in the physician's judgment, may interfere with participation in the study.",{"count":131,"type":23},620,[98],"Phase III clinical trial to evaluate the efficacy and safety of a fixed-dose combination of 1000 mg dipyrone monohydrate + 60 mg caffeine + 4 mg chlorpheniramine maleate in improving symptoms of the common cold and flu in adults.",[135,136,137],"Common Cold\u002FFlu","Nasal Congestion","Nasal Obstruction",[139,140,141,142,143,144,145,146],"nasal congestion","flu","cold","dipyrone","dipyrone monohydrate","caffeine","chlorpheniramine maleate","nasal obstruction","2026-06-15",{"date":149,"type":34},"2026-06-16",{"date":151,"type":34},"2026-05-08",{"date":153,"type":23},"2027-06-30",{"name":40,"class":41},""]